Left Ventricular Hypertrophy in Hypertensive Adolescents
Karen L. McNiece(AstraZeneca (United Kingdom)), Ronald J. Portman(The University of Texas Health Science Center at Houston), Timothy Poffenbarger(AstraZeneca (United Kingdom)), Cynthia Bell(World Health Organization - Pakistan), Monesha Gupta‐Malhotra(AstraZeneca (United Kingdom)), Kathleen Garcia(AstraZeneca (United Kingdom)), Joshua Samuels(AstraZeneca (United Kingdom)), Jonathan M. Sorof(AstraZeneca (United Kingdom))
Cited by 219
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Prevalence of Hypertension in Children
|Hypertension|2018|210
Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial
|American Journal of Kidney Diseases|2013|177
Race and Obesity in Adolescent Hypertension
|PEDIATRICS|2017|143